Fluids and Barriers of the CNS · 2018 · 118 citations · 41 references
Life SciencesNeurobiologyNeuroscienceGene ExpressionMolecular NeuroscienceTranscriptomicsAlzheimer DiseaseGlial Gene ExpressionHuntington DiseaseNeurodegenerative DiseasesNeurodegenerative DisordersNeuropathology Of DementiaAlzheimer Disease DementiaAlzheimer’s Disease Barrier DysfunctionBlood-cerebrospinal Fluid Barrier DysfunctionBlood-cerebrospinal Fluid Barrier TransportChoroid Plexus InterfaceDifferential Transcript ExpressionGlial Gene Expression ProfilingNeuronal Gene Expression Profiling
BACKGROUND: In Alzheimer's disease, there are striking changes in CSF composition that relate to altered choroid plexus (CP) function. Studying CP tissue gene expression at the blood-cerebrospinal fluid barrier could provide further insight into the epithelial and stromal responses to neurodegenerative disease states. METHODS: Transcriptome-wide Affymetrix microarrays were used to determine disease-related changes in gene expression in human CP. RNA from post-mortem samples of the entire lateral ventricular choroid plexus was extracted from 6 healthy controls (Ctrl), 7 patients with advanced (Braak and Braak stage III-VI) Alzheimer's disease (AD), 4 with frontotemporal dementia (FTD) and 3 with Huntington's disease (HuD). Statistics and agglomerative clustering were accomplished with MathWorks, MatLab; and gene set annotations by comparing input sets to GeneGo ( http://www.genego.com ) and Ingenuity ( http://www.ingenuity.com ) pathway sets. Bonferroni-corrected hypergeometric p-values of < 0.1 were considered a significant overlap between sets. RESULTS: Pronounced differences in gene expression occurred in CP of advanced AD patients vs. Ctrls. Metabolic and immune-related pathways including acute phase response, cytokine, cell adhesion, interferons, and JAK-STAT as well as mTOR were significantly enriched among the genes upregulated. Methionine degradation, claudin-5 and protein translation genes were downregulated. Many gene expression changes in AD patients were observed in FTD and HuD (e.g., claudin-5, tight junction downregulation), but there were significant differences between the disease groups. In AD and HuD (but not FTD), several neuroimmune-modulating interferons were significantly enriched (e.g., in AD: IFI-TM1, IFN-AR1, IFN-AR2, and IFN-GR2). AD-associated expression changes, but not those in HuD and FTD, were enriched for upregulation of VEGF signaling and immune response proteins, e.g., interleukins. HuD and FTD patients distinctively displayed upregulated cadherin-mediated adhesion. CONCLUSIONS: Our transcript data for human CP tissue provides genomic and mechanistic insight for differential expression in AD vs. FTD vs. HuD for stromal as well as epithelial components. These choroidal transcriptome characterizations elucidate immune activation, tissue functional resiliency, and CSF metabolic homeostasis. The BCSFB undergoes harmful, but also important functional and adaptive changes in neurodegenerative diseases; accordingly, the enriched JAK-STAT and mTOR pathways, respectively, likely help the CP in adaptive transcription and epithelial repair and/or replacement when harmed by neurodegeneration pathophysiology. We anticipate that these precise CP translational data will facilitate pharmacologic/transgenic therapies to alleviate dementia.
41
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Hadas Keren‐Shaul, Amit Spinrad, Assaf Weiner et al. · Cell · 2017 · 5.6K citations · Full text
Folate, Vitamin B12, and Serum Total Homocysteine Levels in Confirmed Alzheimer Disease
Robert Clarke, A. David Smith, Kim A. Jobst et al. · Archives of Neurology · 1998 · 1.4K citations
Medicine, Geriatric Medicine, Aging +16